Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
15 studies found for:    HSPPC-96
Show Display Options
Rank Status Study
1 Completed HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
Condition: Brain and Central Nervous System Tumors
Intervention: Biological: HSPPC-96
2 Withdrawn Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma
Condition: Melanoma
Interventions: Drug: ipilimumab;   Drug: HSPPC-96
3 Terminated Immune Response Following Treatment of Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
Condition: Renal Cell Carcinoma
Intervention: Biological: HSPPC-96
4 Recruiting Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Condition: Glioblastoma
Interventions: Drug: Pembrolizumab;   Biological: HSPPC-96;   Drug: Temozolomide;   Other: Placebo;   Radiation: radiation treatment
5 Completed Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer
Conditions: Non-Small-Cell Lung Carcinoma;   Lung Cancer;   Pulmonary Cancer
Intervention: Biological: HSPPC-96
6 Completed Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma
Condition: Malignant Melanoma
Intervention: Drug: HSPPC-96 or Oncophage
7 Recruiting Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine
Conditions: Glioblastoma Multiforme;   Astrocytoma, Grade III;   Anaplastic Ependymoma;   Clear Cell Ependymoma;   Ependymoma
Interventions: Biological: Heat Shock Protein Peptide Complex-96 (HSPPC-96);   Procedure: Tumor Resection;   Radiation: Radiation
8 Terminated Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Intervention: Biological: autologous human tumor-derived HSPPC-96
9 Terminated Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer
Conditions: Kidney Cancer;   Renal Cell Carcinoma
Intervention: Biological: HSPPC-96
10 Completed GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: HSPPC-96;   Procedure: conventional surgery
11 Completed Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer
Condition: Renal Cell Carcinoma
Intervention: Drug: autologous human tumor-derived HSPPC-96
12 Completed A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma
Conditions: Lymphoma, Follicular;   Lymphoma, Small Lymphocytic
Intervention: Drug: autologous human tumor-derived HSPPC-96
13 Active, not recruiting Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Conditions: Recurrent Glioblastoma;   Recurrent Adult Brain Tumor;   Gliosarcoma
Interventions: Biological: HSPPC-96;   Drug: bevacizumab
14 Completed Vaccine Therapy in Treating Patients With Recurrent Soft Tissue Sarcoma
Condition: Sarcoma
Intervention: Biological: vitespen
15 Completed Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Biological: vitespen

Study has passed its completion date and status has not been verified in more than two years.